Beam Therapeutics Inc. NMS · BEAM

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?

The Motley Fool · 3d ago

Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth Forecast

GlobeNewswire Inc. · 20d ago

Global CRISPR-Based Drug Development Platforms Market to Reach USD 0.79 Billion by 2031: Precision Medicine and Gene Therapy Drive Growth

GlobeNewswire Inc. · 20d ago

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?

The Motley Fool · 58d ago

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

GlobeNewswire Inc. · 65d ago

S&P 500 Holds Near Highs Despite Oil Shock and Weak Breadth Data

Investing.com · 87d ago

3 Biotech Stocks That Could Benefit from the Patent Cliff

Investing.com · 87d ago

Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.

The Motley Fool · 103d ago

Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications

GlobeNewswire Inc. · 107d ago

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

GlobeNewswire Inc. · 120d ago

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

GlobeNewswire Inc. · 149d ago

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

GlobeNewswire Inc. · 149d ago

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

GlobeNewswire Inc. · 149d ago

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

GlobeNewswire Inc. · 229d ago

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

The Motley Fool · 390d ago

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

The Motley Fool · 401d ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

GlobeNewswire Inc. · 419d ago

Why Beam Therapeutics Stock Tanked on Tuesday

The Motley Fool · 442d ago

Beam Therapeutics Announces Pricing of Underwritten Offering

GlobeNewswire Inc. · 500d ago

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

GlobeNewswire Inc. · 514d ago

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

GlobeNewswire Inc. · 539d ago

Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight

GlobeNewswire Inc. · 581d ago

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

GlobeNewswire Inc. · 592d ago

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

GlobeNewswire Inc. · 594d ago

Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?

The Motley Fool · 606d ago